Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland—A multicentre cohort study
暂无分享,去创建一个
L. Risch | M. Schlegel | S. Güsewell | P. Rieder | C. Kahlert | P. Kohler | D. Vuichard-Gysin | A. Friedl | B. Wiggli | A. Brucher | R. Stocker | U. Besold | H. Schmid | E. Lemmenmeier | A. McGeer | J. C. Möller | S. Kuster | T. Egger | D. Meier Kleeb | B. Babouee Flury | Onicio Leal | Markus Rütti | Baharak Babouee Flury
[1] A. Cook,et al. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age , 2022, The New England journal of medicine.
[2] K. Mølbak,et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data , 2022, The Lancet Regional Health - Europe.
[3] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[4] Michael I. Mandel,et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 , 2022, The New England journal of medicine.
[5] Lauren E. W. Olsho,et al. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers , 2022, The New England journal of medicine.
[6] A. Robicsek,et al. Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 , 2022, JAMA network open.
[7] C. Steves,et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.
[8] A. Nordström,et al. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden , 2022, The Lancet Infectious Diseases.
[9] Jeffrey M. Wilson,et al. Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection , 2022, Frontiers in Immunology.
[10] Gheyath K Nasrallah,et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.
[11] Gheyath K Nasrallah,et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.
[12] E. Theel,et al. Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It? , 2022, Journal of clinical microbiology.
[13] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.
[14] Y. Maor,et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine , 2022, Nature Communications.
[15] A. Charlett,et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection , 2022, The New England journal of medicine.
[16] Gheyath K Nasrallah,et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.
[17] S. Madhi,et al. SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers , 2022, medRxiv.
[18] U. Dafni,et al. Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period , 2022, Journal of Infection.
[19] S. Arifeen,et al. COVID-19 reinfections among naturally infected and vaccinated individuals , 2022, Scientific Reports.
[20] S. Schrag,et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.
[21] L. Abu-Raddad,et al. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar , 2022, The New England journal of medicine.
[22] D. von Laer,et al. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons , 2022, The New England journal of medicine.
[23] C. Maslo,et al. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. , 2021, JAMA.
[24] D. Wesemann,et al. Antibody Dynamics and Durability in Coronavirus Disease-19 , 2021, Clinics in Laboratory Medicine.
[25] L. Abu-Raddad,et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. , 2021, JAMA.
[26] L. Risch,et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort , 2021, medRxiv.
[27] I. Diamond,et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.
[28] A. Nordström,et al. Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members , 2021, JAMA internal medicine.
[29] A. Galvani,et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis , 2021, Proceedings of the National Academy of Sciences.
[30] E. Grundberg,et al. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals , 2021, BMC Medicine.
[31] L. Risch,et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study , 2021, BMC Medicine.
[32] L. Risch,et al. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers – A multicentre cross-sectional study , 2021, Clinical Microbiology and Infection.
[33] L. Stamatatos,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.
[34] Nguyen H. Tran,et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.
[35] L. Risch,et al. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers – A multicentre cross-sectional study , 2020, Clinical Microbiology and Infection.
[36] L. Risch,et al. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study , 2020, Clinical chemistry and laboratory medicine.
[37] A. Tatem,et al. The risk of COVID-19 transmission in train passengers: an epidemiological and modelling study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.